Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 8Gastrointestinal 5Thoracic 2Genitourinary 2Sarcoma 1Head & Neck 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 41Colorectal Neoplasms 15Lung Neoplasms 12Ovarian Neoplasms 6Stomach Neoplasms 5Pancreatic Neoplasms 5Neoplasms 5Rectal Neoplasms 4Neoplasm Metastasis 4Melanoma 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Recurrence 3Mesothelioma 3Carcinoma, Pancreatic Ductal 3Peritoneal Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Breast Neoplasms 2Vipoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Spinocerebellar Degenerations 1Somatostatinoma 1Skin Neoplasms 1

Interventions

pembrolizumab 30Carboplatin 13Trastuzumab 8Paclitaxel 7Nivolumab 7Cisplatin 6Ipilimumab 5Cetuximab 5Bevacizumab 5Taxes 4Pemetrexed 4Specimen Handling 3Irinotecan 3Docetaxel 3Cyclophosphamide 3Biopsy 3tisotumab vedotin 2temsirolimus 2spartalizumab 2sargramostim 2pertuzumab 2lenvatinib 2fludarabine 2epacadostat 2enzalutamide 2aldesleukin 2X-Rays 2Ritonavir 2Psychiatric Rehabilitation 2Oxaliplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Oxaliplatin × Thoracic × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT07453394 2026-03-06

QLS5132 Combination Therapy in Advanced Solid Tumors

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Not yet recruiting
626 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡